Aeon Global Health (AGHC) versus The Competition Critical Analysis

Aeon Global Health (OTCMKTS: AGHC) is one of 23 public companies in the “Medical laboratories” industry, but how does it contrast to its competitors? We will compare Aeon Global Health to related businesses based on the strength of its analyst recommendations, institutional ownership, risk, earnings, dividends, profitability and valuation.

Institutional & Insider Ownership

52.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 11.5% of Aeon Global Health shares are owned by insiders. Comparatively, 17.4% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Aeon Global Health has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Aeon Global Health’s competitors have a beta of 1.37, suggesting that their average share price is 37% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Aeon Global Health and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aeon Global Health 0 0 1 0 3.00
Aeon Global Health Competitors 137 566 671 36 2.43

As a group, “Medical laboratories” companies have a potential upside of 18.69%. Given Aeon Global Health’s competitors higher probable upside, analysts plainly believe Aeon Global Health has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Aeon Global Health and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aeon Global Health $16.30 million -$8.00 million -0.59
Aeon Global Health Competitors $1.13 billion $90.54 million 463.41

Aeon Global Health’s competitors have higher revenue and earnings than Aeon Global Health. Aeon Global Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Aeon Global Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aeon Global Health -43.04% -337.14% -61.39%
Aeon Global Health Competitors -103.54% -222.38% -36.27%

Summary

Aeon Global Health competitors beat Aeon Global Health on 10 of the 13 factors compared.

Aeon Global Health Company Profile

AEON Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through two segments, Laboratory Testing Services and Web-Based Software. Its laboratory testing services include the testing of an individual's blood, urine, or saliva for the presence of drugs or chemicals, as well as the patient's DNA profile. The company primarily offers medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. It also provides Web-based services as software as a service for Web-based revenue cycle management applications; and telehealth products and services that enable healthcare organizations to coordinate care for patients, and enhance related administrative and clinical workflows, and compliance with regulatory requirements. In addition, AEON Global Health Corp. offers post contract customer support services. The company was formerly known as Authentidate Holding Corp. and changed its name to AEON Global Health Corp. in January 2018. AEON Global Health Corp. is based in Gainesville, Georgia.

Receive News & Ratings for Aeon Global Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeon Global Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit